MiR-935 Promotes Clear Cell Renal Cell Carcinoma Migration and Invasion by Targeting IREB2 [Retraction]
Authors Liu F, Chen Y, Chen B, Liu C, Xing J
Received 7 August 2020
Accepted for publication 7 August 2020
Published 17 August 2020 Volume 2020:12 Pages 7319—7320
Liu F, Chen Y, Chen B, Liu C, Xing J. Cancer Manag Res. 2019;11:10891–10900.
At the authors request, the Editor-in-Chief and Publisher of Cancer Management and Research wish to retract the published article.
Following a review of their article the authors found some errors had been made in Figure 4E, specifically images in panels Migration miR-935 inhibitor +/si-IREB2 + and Invasion miR-935 inhibitor +/si-IREB2 +. After carefully going through the raw data for their study the authors were unable to locate the original images for Figure 4E. The authors were also unable to locate the original images for the western blots shown in the article. Both the editor and authors determined the findings of this study could no longer be supported and agreed for the article to be retracted.
The authors wish to apologise for this error.
Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
This retraction relates to this paper
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]